Reports Q2 revenue $124.1M, consensus $115.5M. “Our record second quarter results reflect a sustained growth acceleration in our business driven by successful global execution of our key strategic plans,” said Thomas Burns, Glaukos (GKOS) chairman and chief executive officer. “We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Notable companies reporting after market close
- Glaukos price target raised to $117 from $114 at BTIG
- Glaukos announces E.U. MDR certification for iStent infinite
- Glaukos Positioned for Growth with Innovative Epioxa Therapy and First-Mover Advantage in Keratoconus Treatment
- Promising Outlook for Glaukos: Strategic Advancements and Market Growth Drive Buy Rating